Transforming growth factor-beta-induced protein secreted by peritoneal cells increases the metastatic potential of ovarian cancer cells - PubMed (original) (raw)
. 2011 Apr 1;128(7):1570-84.
doi: 10.1002/ijc.25494. Epub 2010 Jun 2.
Affiliations
- PMID: 20521251
- DOI: 10.1002/ijc.25494
Transforming growth factor-beta-induced protein secreted by peritoneal cells increases the metastatic potential of ovarian cancer cells
Miranda P Ween et al. Int J Cancer. 2011.
Abstract
Ovarian cancer metastasis is characterized by the shedding of malignant cells from the surface of the ovary and their implantation onto the peritoneal surface, which lines the abdominal cavity. As the factors promoting this process are poorly understood, we investigated the ovarian cancer-peritoneal interaction by means of in vitro coculture experiments with ovarian cancer (OVCAR-5 and SKOV-3) and peritoneal (LP-9) cells. One of the proteins differentially expressed in the coculture secretome was identified by MALDI-TOF/TOF mass spectrometry as the extracellular matrix protein transforming growth factor-beta-induced protein (TGFBIp, also known as βig-H3). Immunohistochemistry showed high TGFBIp levels in normal surface ovarian epithelial and peritoneal cells, whereas TGFBIp levels in primary serous ovarian carcinomas and matching metastatic implants was very low. In functional in vitro experiments, treatment with recombinant TGFBIp significantly increased the motility and invasiveness of OVCAR-5 and SKOV-3 cells and significantly increased ovarian cancer cell (OVCAR-5, OVCAR-3 and SKOV-3) adhesion to LP-9 cells. TGFBIp was found to be processed at both the N- and C-terminus in the secretome of the ovarian cancer-peritoneal cell coculture. Plasmin inhibitors blocked TGFBIp processing and significantly reduced OVCAR-5 cell adhesion to peritoneal cells. We conclude that TGFBIp expressed by peritoneal cells increases the metastatic potential of ovarian cancer cells. TGFBIp is therefore a potential novel therapeutic target against ovarian cancer.
Copyright © 2010 UICC.
Similar articles
- Transketolase is upregulated in metastatic peritoneal implants and promotes ovarian cancer cell proliferation.
Ricciardelli C, Lokman NA, Cheruvu S, Tan IA, Ween MP, Pyragius CE, Ruszkiewicz A, Hoffmann P, Oehler MK. Ricciardelli C, et al. Clin Exp Metastasis. 2015 Jun;32(5):441-55. doi: 10.1007/s10585-015-9718-1. Epub 2015 Apr 21. Clin Exp Metastasis. 2015. PMID: 25895698 - The activated transforming growth factor-beta signaling pathway in peritoneal metastases is a potential therapeutic target in ovarian cancer.
Yamamura S, Matsumura N, Mandai M, Huang Z, Oura T, Baba T, Hamanishi J, Yamaguchi K, Kang HS, Okamoto T, Abiko K, Mori S, Murphy SK, Konishi I. Yamamura S, et al. Int J Cancer. 2012 Jan 1;130(1):20-8. doi: 10.1002/ijc.25961. Epub 2011 Apr 18. Int J Cancer. 2012. PMID: 21503873 - βig-h3 CORRELATES WITH RELATED FACTORS OF PERITONEAL METASTASIS OF GASTRIC CANCER.
Wang F, Li XW, Lu WB, Jin JH. Wang F, et al. J Biol Regul Homeost Agents. 2015 Jan-Mar;29(1):181-6. J Biol Regul Homeost Agents. 2015. PMID: 25864756 - Transforming growth Factor-Beta-Induced Protein (TGFBI)/(βig-H3): a matrix protein with dual functions in ovarian cancer.
Ween MP, Oehler MK, Ricciardelli C. Ween MP, et al. Int J Mol Sci. 2012;13(8):10461-10477. doi: 10.3390/ijms130810461. Epub 2012 Aug 21. Int J Mol Sci. 2012. PMID: 22949874 Free PMC article. Review. - WOMEN IN CANCER THEMATIC REVIEW: Ovarian cancer-peritoneal cell interactions promote extracellular matrix processing.
Ricciardelli C, Lokman NA, Ween MP, Oehler MK. Ricciardelli C, et al. Endocr Relat Cancer. 2016 Nov;23(11):T155-T168. doi: 10.1530/ERC-16-0320. Epub 2016 Aug 30. Endocr Relat Cancer. 2016. PMID: 27578826 Review.
Cited by
- Proteomic identification of betaig-h3 as a lysophosphatidic acid-induced secreted protein of human mesenchymal stem cells: paracrine activation of A549 lung adenocarcinoma cells by betaig-h3.
Shin SH, Kim J, Heo SC, Kwon YW, Kim YM, Kim IS, Lee TG, Kim JH. Shin SH, et al. Mol Cell Proteomics. 2012 Feb;11(2):M111.012385. doi: 10.1074/mcp.M111.012385. Epub 2011 Dec 7. Mol Cell Proteomics. 2012. PMID: 22159598 Free PMC article. - Annexin A2 is regulated by ovarian cancer-peritoneal cell interactions and promotes metastasis.
Lokman NA, Elder AS, Ween MP, Pyragius CE, Hoffmann P, Oehler MK, Ricciardelli C. Lokman NA, et al. Oncotarget. 2013 Aug;4(8):1199-211. doi: 10.18632/oncotarget.1122. Oncotarget. 2013. PMID: 23945256 Free PMC article. - Comparative proteomic analysis of normal and collagen IX null mouse cartilage reveals altered extracellular matrix composition and novel components of the collagen IX interactome.
Brachvogel B, Zaucke F, Dave K, Norris EL, Stermann J, Dayakli M, Koch M, Gorman JJ, Bateman JF, Wilson R. Brachvogel B, et al. J Biol Chem. 2013 May 10;288(19):13481-92. doi: 10.1074/jbc.M112.444810. Epub 2013 Mar 24. J Biol Chem. 2013. PMID: 23530037 Free PMC article. - ß3 integrin modulates transforming growth factor beta induced (TGFBI) function and paclitaxel response in ovarian cancer cells.
Tumbarello DA, Temple J, Brenton JD. Tumbarello DA, et al. Mol Cancer. 2012 May 28;11:36. doi: 10.1186/1476-4598-11-36. Mol Cancer. 2012. PMID: 22640878 Free PMC article. - ABCA1 is associated with the development of acquired chemotherapy resistance and predicts poor ovarian cancer outcome.
Wang W, Lokman NA, Noye TM, Macpherson AM, Oehler MK, Ricciardelli C. Wang W, et al. Cancer Drug Resist. 2021 Jun 19;4(2):485-502. doi: 10.20517/cdr.2020.107. eCollection 2021. Cancer Drug Resist. 2021. PMID: 35582032 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials